by 
Insulin lispro is a fast acting insulin analogue used for the management of blood glucose levels in diabetics. It works more rapidly and for a shorter duration than regular human insulin. Insulin lispro is sold under the brand name ‘Humalog’ and is available in formulation such as injection vials and prefilled insulin pens. It is preferred in treatment of diabetes where a rapid onset and short duration of action is needed such as pre-meal administration. The global insulin lispro market is driven by the rising prevalence of diabetes across the world. Diabetes is projected to be the 7th leading cause of death by 2030. This continuous increase poses significant burden on healthcare systems and patients with diabetes requiring efficient management and treatment options.
The global Insulin Lispro Market is estimated to be valued at US$ 7.32 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The global insulin lispro market is witnessing a key trend of adoption of premixed insulin analogues containing lispro. Premix insulin analogues provide combination of basal and bolus insulin in one formulation thereby simplifying treatment regimen for patients. Popular premixed insulin analogues containing lispro include Humalog Mix 75/25 and Humalog Mix 50/50. Continuous technology advancements are also being made to develop novel drug delivery devices for insulin. Companies are focusing on development of smart insulin pens and artificial pancreas devices integrated with continuous glucose monitoring for automated insulin delivery. These innovations aim to enhance patient safety, convenience and glycemic control. Furthermore, in combating rising healthcare costs, payers and providers are shifting focus towards value based care models. This involves reimbursement and coverage for cost effective biosimilars of insulin lispro which will favor market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low in insulin lispro market due to high capital requirements and research and development costs. Additionally, established brands have strong customer loyalty and distribution networks.
Bargaining power of buyers: The bargaining power of buyers is moderate due to presence of a large number of pharmaceutical manufacturers offering insulin lispro. However, demand for insulin lispro drugs is inelastic.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of substitute raw materials and the fragmented nature of suppliers.
Threat of new substitutes: The threat of new substitutes is moderate as alternate analog insulins and biosimilars continue to be developed and commercialized.
Competitive rivalry: The competitive rivalry is high among key players like Eli Lilly and Company, Sanofi, Novo Nordisk A/S due to their global presence and extensive R&D capabilities.
Key Takeaways
The global insulin lispro market is expected to witness high growth over the forecast period. North America region currently dominates the market and is expected to continue its dominance over the forecast period. Factors such as high prevalence of diabetes, favorable reimbursement policies, and presence of key players in the region drive the growth of the regional market.
Key players operating in the insulin lispro market are Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., Gan & Lee Pharmaceuticals and Ypsomed AG. Eli Lilly and Company is a leading player with its innovative insulin lispro drugs such as Humalog. It has strong foothold in the US market. Sanofi also offers insulin lispro under Lantus brand and has significant market share globally.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
